1
|
Lhamyani S, Gentile AM, Mengual-Mesa M, Grueso E, Giráldez-Pérez RM, Fernandez-Garcia JC, Vega-Rioja A, Clemente-Postigo M, Pearson JR, González-Mariscal I, Olveira G, Bermudez-Silva FJ, El Bekay R. Au@16-pH-16/miR-21 mimic nanosystem: An efficient treatment for obesity through browning and thermogenesis induction. Biomed Pharmacother 2024; 171:116104. [PMID: 38198956 DOI: 10.1016/j.biopha.2023.116104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 12/21/2023] [Accepted: 12/26/2023] [Indexed: 01/12/2024] Open
Abstract
Despite the abundance of registered clinical trials worldwide, the availability of effective drugs for obesity treatment is limited due to their associated side effects. Thus, there is growing interest in therapies that stimulate energy expenditure in white adipose tissue. Recently, we demonstrated that the delivery of a miR-21 mimic using JetPEI effectively inhibits weight gain in an obese mouse model by promoting metabolism, browning, and thermogenesis, suggesting the potential of miR-21 mimic as a treatment for obesity. Despite these promising results, the implementation of more advanced delivery system techniques for miR-21 mimic would greatly enhance the advancement of safe and efficient treatment approaches for individuals with obesity in the future. Our objective is to explore whether a new delivery system based on gold nanoparticles and Gemini surfactants (Au@16-ph-16) can replicate the favorable effects of the miR-21 mimic on weight gain, browning, and thermogenesis. We found that dosages as low as 0.2 μg miR-21 mimic /animal significantly inhibited weight gain and induced browning and thermogenic parameters. This was evidenced by the upregulation of specific genes and proteins associated with these processes, as well as the biogenesis of beige adipocytes and mitochondria. Significant increases in miR-21 levels were observed in adipose tissue but not in other tissue types. Our data indicates that Au@16-ph-16 could serve as an effective delivery system for miRNA mimics, suggesting its potential suitability for the development of future clinical treatments against obesity.
Collapse
Affiliation(s)
- Said Lhamyani
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain; Obesity and Nutrition CIBER (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain
| | - Adriana-Mariel Gentile
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain
| | - María Mengual-Mesa
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Universidad de Málaga. Andalucía Tech, Faculty of Health Sciences, Department of Systems and Automation Engineering, Malaga, Spain
| | - Elia Grueso
- Departamento de Física Química, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain
| | - Rosa M Giráldez-Pérez
- Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain
| | - José Carlos Fernandez-Garcia
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain; Obesity and Nutrition CIBER (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain
| | - Antonio Vega-Rioja
- Laboratorio de Inmunología y Alergia-FISEVI, UGC de Alergología. Hospital Universitario Virgen Macarena, Sevilla, Spain; Departamento de Medicina. Facultad de Medicina. Universidad de Sevilla, Sevilla, Spain
| | - Mercedes Clemente-Postigo
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Obesity and Nutrition CIBER (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain; Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Malaga, Spain; Department of Cell Biology, Genetics, and Physiology, Faculty of Science, University of Malaga, Malaga, Spain
| | - John R Pearson
- Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain
| | - Isabel González-Mariscal
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Inserm UMR1190, CHU de Lille, Universite de Lille, Institute Pasteur de Lille, Lille, France
| | - Gabriel Olveira
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain; The Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain; Departamento de Medicina y Cirugía, Universidad de Málaga, Málaga, Spain
| | - Francisco-Javier Bermudez-Silva
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain; The Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
| | - Rajaa El Bekay
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain; Obesity and Nutrition CIBER (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
2
|
Gentile AM, Lhamyani S, Mengual-Mesa M, García-Fuentes E, Bermúdez-Silva FJ, Rojo-Martínez G, Clemente-Postigo M, Rodriguez-Cañete A, Olveira G, El Bekay R. MiR-221-3p/222-3p Cluster Expression in Human Adipose Tissue Is Related to Obesity and Type 2 Diabetes. Int J Mol Sci 2023; 24:17449. [PMID: 38139277 PMCID: PMC10744326 DOI: 10.3390/ijms242417449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 12/05/2023] [Accepted: 12/09/2023] [Indexed: 12/24/2023] Open
Abstract
The progression of obesity and type 2 diabetes (T2D) is intricately linked with adipose tissue (AT) angiogenesis. Despite an established network of microRNAs (miRNAs) regulating AT function, the specific role of angiogenic miRNAs remains less understood. The miR-221/222 cluster has recently emerged as being associated with antiangiogenic activity. However, no studies have explored its role in human AT amidst the concurrent development of obesity and T2D. Therefore, this study aims to investigate the association between the miR-221-3p/222-3p cluster in human AT and its regulatory network with obesity and T2D. MiR-221-3p/222-3p and their target gene (TG) expression levels were quantified through qPCR in visceral (VAT) and subcutaneous (SAT) AT from patients (n = 33) categorized based on BMI as normoweight (NW) and obese (OB) and by glycemic status as normoglycemic (NG) and type 2 diabetic (T2D) subjects. In silico analyses of miR-221-3p/222-3p and their TGs were conducted to identify pertinent signaling pathways. The results of a multivariate analysis, considering the simultaneous expression of miR-221-3p and miR-222-3p as dependent variables, revealed statistically significant distinctions when accounting for variables such as tissue depot, obesity, sex, and T2D as independent factors. Furthermore, both miRNAs and their TGs exhibited differential expression patterns based on obesity severity, glycemic status, sex, and type of AT depot. Our in silico analysis indicated that miR-221-3p/222-3p cluster TGs predominantly participate in angiogenesis, WNT signaling, and apoptosis pathways. In conclusion, these findings underscore a promising avenue for future research, emphasizing the miR-221-3p/222-3p cluster and its associated regulatory networks as potential targets for addressing obesity and related metabolic disorders.
Collapse
Affiliation(s)
- Adriana-Mariel Gentile
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Málaga, Spain; (A.-M.G.); (S.L.); (E.G.-F.); (F.-J.B.-S.); (G.R.-M.); (G.O.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Málaga, 29009 Málaga, Spain
| | - Said Lhamyani
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Málaga, Spain; (A.-M.G.); (S.L.); (E.G.-F.); (F.-J.B.-S.); (G.R.-M.); (G.O.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Málaga, 29009 Málaga, Spain
- Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBERObn), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - María Mengual-Mesa
- Andalucía Tech, Faculty of Health Sciences, Department of Systems and Automation Engineering, School of Industrial Engineering, Universidad de Málaga, Teatinos Campus, 29071 Málaga, Spain;
| | - Eduardo García-Fuentes
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Málaga, Spain; (A.-M.G.); (S.L.); (E.G.-F.); (F.-J.B.-S.); (G.R.-M.); (G.O.)
- Unidad de Gestión Clínica de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Málaga, Spain
| | - Francisco-Javier Bermúdez-Silva
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Málaga, Spain; (A.-M.G.); (S.L.); (E.G.-F.); (F.-J.B.-S.); (G.R.-M.); (G.O.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Málaga, 29009 Málaga, Spain
- The Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Gemma Rojo-Martínez
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Málaga, Spain; (A.-M.G.); (S.L.); (E.G.-F.); (F.-J.B.-S.); (G.R.-M.); (G.O.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Málaga, 29009 Málaga, Spain
- The Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Mercedes Clemente-Postigo
- Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, 29010 Málaga, Spain
- Institute of Biomedical Research in Málaga (IBIMA)-Bionand Platform, 29590 Málaga, Spain
- Department of Cell Biology, Genetics, and Physiology, Faculty of Science, University of Málaga, 29010 Málaga, Spain
| | - Alberto Rodriguez-Cañete
- Unidad de Gestión Clínica de Cirugía General, Digestiva y Trasplantes, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain;
| | - Gabriel Olveira
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Málaga, Spain; (A.-M.G.); (S.L.); (E.G.-F.); (F.-J.B.-S.); (G.R.-M.); (G.O.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Málaga, 29009 Málaga, Spain
- The Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
- Departamento de Medicina y Cirugía, Universidad de Málaga, 29010 Málaga, Spain
| | - Rajaa El Bekay
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Málaga, Spain; (A.-M.G.); (S.L.); (E.G.-F.); (F.-J.B.-S.); (G.R.-M.); (G.O.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Málaga, 29009 Málaga, Spain
- Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBERObn), Instituto de Salud Carlos III, 28029 Madrid, Spain
- IBIMA-Plataforma Bionand, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain
| |
Collapse
|
3
|
Gentile AM, Lhamyani S, Mengual Mesa M, Pavón-Morón FJ, Pearson JR, Salas J, Clemente-Postigo M, Pérez Costillas L, Fuster GO, El Bekay Rizky R. A Network Comprised of miR-15b and miR-29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects. Int J Mol Sci 2023; 24:14456. [PMID: 37833902 PMCID: PMC10572810 DOI: 10.3390/ijms241914456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 09/09/2023] [Accepted: 09/16/2023] [Indexed: 10/15/2023] Open
Abstract
As the human thymus ages, it undergoes a transformation into adipose tissue known as TAT. Interestingly, in previous research, we observed elevated levels of vascular endothelial growth factor A (VEGFA) in TAT from patients with ischemic cardiomyopathy (IC), particularly in those over 70 years old. Moreover, in contrast to subcutaneous adipose tissue (SAT), TAT in elderly individuals exhibits enhanced angiogenic properties and the ability to stimulate tube formation. This makes TAT a promising candidate for angiogenic therapies and the regeneration of ischemic tissues following coronary surgery. MicroRNAs (miRNAs) have emerged as attractive therapeutic targets, especially those that regulate angiogenic processes. The study's purpose is to determine the miRNA network associated with both the VEGFA pathway regulation and the enrichment of age-linked angiogenesis in the TAT. RT-PCR was used to analyze angiogenic miRNAs and the expression levels of their predicted target genes in both TAT and SAT from elderly and middle-aged patients treated with coronary artery bypass graft surgery. miRTargetLink Human was used to search for miRNAs and their target genes. PANTHER was used to annotate the biological processes of the predicted targets. The expression of miR-15b-5p and miR-29a-3p was significantly upregulated in the TAT of elderly compared with middle-aged patients. Interestingly, VEGFA and other angiogenic targets were significantly upregulated in the TAT of elderly patients. Specifically: JAG1, PDGFC, VEGFA, FGF2, KDR, NOTCH2, FOS, PDGFRA, PDGFRB, and RHOB were upregulated, while PIK3CG and WNT7A were downregulated. Our results provide strong evidence of a miRNA/mRNA interaction network linked with age-associated TAT angiogenic enrichment in patients with IC.
Collapse
Affiliation(s)
- Adriana Mariel Gentile
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; (A.M.G.); (S.L.); (M.M.M.); (F.J.P.-M.); (M.C.-P.); (G.O.F.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain
- Andalucía Tech, Faculty of Health Sciences, and Department of Systems and Automation Engineering, School of Industrial Engineering, Universidad de Málaga, Teatinos Campus, s/n, 29071 Málaga, Spain
| | - Said Lhamyani
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; (A.M.G.); (S.L.); (M.M.M.); (F.J.P.-M.); (M.C.-P.); (G.O.F.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain
| | - María Mengual Mesa
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; (A.M.G.); (S.L.); (M.M.M.); (F.J.P.-M.); (M.C.-P.); (G.O.F.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain
- Andalucía Tech, Faculty of Health Sciences, and Department of Systems and Automation Engineering, School of Industrial Engineering, Universidad de Málaga, Teatinos Campus, s/n, 29071 Málaga, Spain
| | - Francisco Javier Pavón-Morón
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; (A.M.G.); (S.L.); (M.M.M.); (F.J.P.-M.); (M.C.-P.); (G.O.F.)
- Clinical Unit of the Cardiology Area, University Hospital Virgen de la Victoria, 29009 Málaga, Spain
- Spain Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Health Institute III, 28029 Madrid, Spain
| | - John R. Pearson
- Biomedicine Institute of Seville (IBiS), 41013 Seville, Spain;
| | - Julián Salas
- Department of Cardiovascular Surgery, University Regional Hospital of Malaga, 29009 Malaga, Spain;
| | - Mercedes Clemente-Postigo
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; (A.M.G.); (S.L.); (M.M.M.); (F.J.P.-M.); (M.C.-P.); (G.O.F.)
- Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofia University Hospital, Department of Cell Biology, Physiology and Immunology, University of Córdoba, 14004 Córdoba, Spain
- Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBERObn), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Lucía Pérez Costillas
- Research Unit, International Institute for Innovation and Care in Neurodevelopment and Language, Department of Psychiatry and Physiotherapy, Faculty of Medicine, University of Malaga, 29010 Malaga, Spain;
| | - Gabriel Olveira Fuster
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; (A.M.G.); (S.L.); (M.M.M.); (F.J.P.-M.); (M.C.-P.); (G.O.F.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain
- Biomedical Research Networking Center on Diabetes and Associated Metabolic Diseases (CIBERDEM), Carlos III Health Institute, 28029 Madrid, Spain
| | - Rajaa El Bekay Rizky
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29580 Malaga, Spain; (A.M.G.); (S.L.); (M.M.M.); (F.J.P.-M.); (M.C.-P.); (G.O.F.)
- Clinical Unit of Endocrinology and Nutrition, University Regional Hospital of Malaga, 29009 Malaga, Spain
- Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition (CIBERObn), Instituto de Salud Carlos III, 28029 Madrid, Spain
| |
Collapse
|
4
|
Ortiz-Alvarez L, Xu H, Di X, Kohler I, Osuna-Prieto FJ, Acosta FM, Vilchez-Vargas R, Link A, Plaza-Díaz J, van der Stelt M, Hankemeier T, Clemente-Postigo M, Tinahones FJ, Gil A, Rensen PCN, Ruiz JR, Martinez-Tellez B. Plasma Levels of Endocannabinoids and Their Analogues Are Related to Specific Fecal Bacterial Genera in Young Adults: Role in Gut Barrier Integrity. Nutrients 2022; 14:2143. [PMID: 35631284 PMCID: PMC9143287 DOI: 10.3390/nu14102143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Revised: 05/12/2022] [Accepted: 05/18/2022] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE To investigate the association of plasma levels of endocannabinoids with fecal microbiota. METHODS Plasma levels of endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), as well as their eleven analogues, and arachidonic acid (AA), were measured using liquid chromatography-tandem mass spectrometry in 92 young adults. DNA extracted from stool samples was analyzed using 16S rRNA gene sequencing. Lipopolysaccharide levels were measured in plasma samples. RESULTS Plasma levels of endocannabinoids and their analogues were not related to beta or alpha diversity indexes. Plasma levels of AEA and related N-acylethanolamines correlated positively with the relative abundance of Faecalibacterium genus (all rho ≥ 0.26, p ≤ 0.012) and Akkermansia genus (all rho ≥ 0.22, p ≤ 0.036), and negatively with the relative abundance of Bilophila genus (all rho ≤ -0.23, p ≤ 0.031). Moreover, plasma levels of 2-AG and other acylglycerols correlated positively with the relative abundance of Parasutterella (all rho ≥ 0.24, p ≤ 0.020) and Odoribacter genera (all rho ≥ 0.27, p ≤ 0.011), and negatively with the relative abundance of Prevotella genus (all rho ≤ -0.24, p ≤ 0.023). In participants with high lipopolysaccharide values, the plasma levels of AEA and related N-acylethanolamines, as well as AA and 2-AG, were negatively correlated with plasma levels of lipopolysaccharide (all rho ≤ -0.24, p ≤ 0.020). CONCLUSION Plasma levels of endocannabinoids and their analogues are correlated to specific fecal bacterial genera involved in maintaining gut barrier integrity in young adults. This suggests that plasma levels of endocannabinoids and their analogues may play a role in the gut barrier integrity in young adults.
Collapse
Affiliation(s)
- Lourdes Ortiz-Alvarez
- PROFITH (PROmoting FITness and Health through Physical Activity) Research Group, Sport and Health University Research Institute (iMUDS), University of Granada, 18071 Granada, Spain; (L.O.-A.); (H.X.); (F.J.O.-P.); (F.M.A.); (B.M.-T.)
- Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain; (J.P.-D.); (A.G.)
| | - Huiwen Xu
- PROFITH (PROmoting FITness and Health through Physical Activity) Research Group, Sport and Health University Research Institute (iMUDS), University of Granada, 18071 Granada, Spain; (L.O.-A.); (H.X.); (F.J.O.-P.); (F.M.A.); (B.M.-T.)
- Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain; (J.P.-D.); (A.G.)
| | - Xinyu Di
- Leiden Academic Centre for Drug Research, Division of Systems Biomedicine and Pharmacology, Leiden University, 2300 Leiden, The Netherlands;
| | - Isabelle Kohler
- Division of BioAnalytical Chemistry, Institute of Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, 1081 Amsterdam, The Netherlands;
- Center for Analytical Sciences Amsterdam, 1098 Amsterdam, The Netherlands
| | - Francisco J. Osuna-Prieto
- PROFITH (PROmoting FITness and Health through Physical Activity) Research Group, Sport and Health University Research Institute (iMUDS), University of Granada, 18071 Granada, Spain; (L.O.-A.); (H.X.); (F.J.O.-P.); (F.M.A.); (B.M.-T.)
- Center for Biomedical Research, Department of Analytical Chemistry, Institute of Nutrition and Food Technology, University of Granada, 18071 Granada, Spain
- Research and Development of Functional Food Center (CIDAF), Health Sciences Technology Park, 18071 Granada, Spain
| | - Francisco M. Acosta
- PROFITH (PROmoting FITness and Health through Physical Activity) Research Group, Sport and Health University Research Institute (iMUDS), University of Granada, 18071 Granada, Spain; (L.O.-A.); (H.X.); (F.J.O.-P.); (F.M.A.); (B.M.-T.)
- Turku PET Centre, University of Turku, 20014 Turku, Finland
- Turku PET Centre, Turku University Hospital, 20521 Turku, Finland
- InFLAMES Research Flagship Centre, University of Turku, 20014 Turku, Finland
| | - Ramiro Vilchez-Vargas
- Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Magdeburg, 39106 Magdeburg, Germany; (R.V.-V.); (A.L.)
| | - Alexander Link
- Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Magdeburg, 39106 Magdeburg, Germany; (R.V.-V.); (A.L.)
| | - Julio Plaza-Díaz
- Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain; (J.P.-D.); (A.G.)
- Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada
| | - Mario van der Stelt
- Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, 2300 Leiden, The Netherlands;
| | - Thomas Hankemeier
- Leiden Academic Centre for Drug Research (LACDR), Department of Systems Biomedicine and Pharmacology, Leiden University, 2300 Leiden, The Netherlands;
| | - Mercedes Clemente-Postigo
- Department of Cell Biology, Physiology and Immunology, Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, 14004 Córdoba, Spain;
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29016 Malaga, Spain;
- Centro de Investigación Biomédica En Red (CIBER), Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Malaga, Spain
| | - Francisco J. Tinahones
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29016 Malaga, Spain;
- Centro de Investigación Biomédica En Red (CIBER), Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Malaga, Spain
| | - Angel Gil
- Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain; (J.P.-D.); (A.G.)
- Centro de Investigación Biomédica En Red (CIBER), Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Malaga, Spain
- Biomedical Research Center, Institute of Nutrition and Food Technology “José Mataix”, University of Granada, Parque Tecnológico Ciencias de la Salud, 18071 Granada, Spain
- Instituto de Investigación Biosanitaria, 18014 Granada, Spain
| | - Patrick C. N. Rensen
- Einthoven Laboratory for Experimental Vascular Medicine, Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2300 Leiden, The Netherlands;
| | - Jonatan R. Ruiz
- PROFITH (PROmoting FITness and Health through Physical Activity) Research Group, Sport and Health University Research Institute (iMUDS), University of Granada, 18071 Granada, Spain; (L.O.-A.); (H.X.); (F.J.O.-P.); (F.M.A.); (B.M.-T.)
- Instituto de Investigación Biosanitaria, 18014 Granada, Spain
- Department of Physical and Sports Education, School of Sports Science, University of Granada, 18071 Granada, Spain
| | - Borja Martinez-Tellez
- PROFITH (PROmoting FITness and Health through Physical Activity) Research Group, Sport and Health University Research Institute (iMUDS), University of Granada, 18071 Granada, Spain; (L.O.-A.); (H.X.); (F.J.O.-P.); (F.M.A.); (B.M.-T.)
- Einthoven Laboratory for Experimental Vascular Medicine, Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2300 Leiden, The Netherlands;
- CERNEP Research Center, Department of Education, Faculty of Education Sciences and SPORT Research Group (CTS-1024), University of Almería, 04120 Almeria, Spain
| |
Collapse
|
5
|
Martín-Núñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ, Moreno-Indias I. Helicobacter pylori Eradication Therapy Affect the Gut Microbiota and Ghrelin Levels. Front Med (Lausanne) 2021; 8:712908. [PMID: 34458288 PMCID: PMC8387937 DOI: 10.3389/fmed.2021.712908] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 07/12/2021] [Indexed: 12/12/2022] Open
Abstract
Background: Antibiotic therapy used to eradicate Helicobacter pylori has been associated with changes in plasma ghrelin and alterations in the gut microbiota. On the other hand, changes in ghrelin levels have been related to changes in gut microbiota composition. Our aim was to evaluate the relationship between changes in the gut microbiota and ghrelin levels in H. pylori infected patients who received antibiotic treatment for its eradication. Methods: A prospective case-control study that included forty H. pylori-positive patients who received eradication therapy (omeprazole, clarithromycin, and amoxicillin) and twenty healthy H. pylori antigen-negative participants. Patients were evaluated, including clinical, anthropometric and dietary variables, before and 2 months after treatment. Gut microbiota composition was analyzed through 16S rRNA amplicon sequencing (IlluminaMiSeq). Results: Changes in gut microbiota profiles and decrease in ghrelin levels were identified after H. pylori eradication treatment. Gut bacteria such as Bifidobacterium longum, Bacteroides, Prevotella, Parabacteroides distasonis, and RS045 have been linked to ghrelin levels fasting and/or post meals. Changes in the abundance of Lachnospiraceae, its genus Blautia, as well as Prevotella stercorea, and Megasphaera have been inversely associated with changes in ghrelin after eradication treatment. Conclusions: Eradication treatment for H. pylori produces changes in the composition of the intestinal microbiota and ghrelin levels. The imbalance between lactate producers such as Blautia, and lactate consumers such as Megasphaera, Lachnospiraceae, or Prevotella, could trigger changes related to ghrelin levels under the alteration of the eradication therapy used for H. pylori. In addition, acetate producing bacteria such as B. longum, Bacteroides, and P. distasonis could also play an important role in ghrelin regulation.
Collapse
Affiliation(s)
- Gracia Mª Martín-Núñez
- Department of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Isabel Cornejo-Pareja
- Department of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Mercedes Clemente-Postigo
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,Department of Cell Biology, Physiology, and Immunology, Maimónides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital, Córdoba, Spain
| | - Francisco J Tinahones
- Department of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Isabel Moreno-Indias
- Department of Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
6
|
Sánchez-Ceinos J, Rangel-Zuñiga OA, Clemente-Postigo M, Podadera-Herreros A, Camargo A, Alcalá-Diaz JF, Guzmán-Ruiz R, López-Miranda J, Malagón MM. miR-223-3p as a potential biomarker and player for adipose tissue dysfunction preceding type 2 diabetes onset. Mol Ther Nucleic Acids 2021; 23:1035-1052. [PMID: 33614249 PMCID: PMC7868931 DOI: 10.1016/j.omtn.2021.01.014] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 01/14/2021] [Indexed: 12/20/2022]
Abstract
Circulating microRNAs (miRNAs) have been proposed as biomarkers for type 2 diabetes (T2D). Adipose tissue (AT), for which dysfunction is widely associated with T2D development, has been reported as a major source of circulating miRNAs. However, the role of dysfunctional AT in the altered pattern of circulating miRNAs associated with T2D onset remains unexplored. Herein, we investigated the relationship between T2D-associated circulating miRNAs and AT function, as well as the role of preadipocytes and adipocytes as secreting cells of candidate circulating miRNAs. Among the plasma miRNAs related to T2D onset in the CORonary Diet Intervention with Olive oil and cardiovascular PREVention (CORDIOPREV) cohort, baseline miR-223-3p levels (diminished in patients who next developed T2D [incident-T2D]) were significantly related to AT insulin resistance (IR). Baseline serum from incident-T2D participants induced inflammation and IR in 3T3-L1 adipocytes. We demonstrated that tumor necrosis factor (TNF)-α inhibited miR-223-3p secretion while enhancing miR-223-3p intracellular accumulation in 3T3-L1 (pre)adipocytes. Overexpression studies showed that an intracellular increase of miR-223-3p impaired glucose and lipid metabolism in these cells. Our findings provide mechanistic insights into the alteration of circulating miRNAs preceding T2D, unveiling both preadipocytes and adipocytes as miR-223-3p-secreting cells and suggesting that inflammation promotes miR-223-3p intracellular accumulation, which might contribute to (pre)adipocyte dysfunction and body metabolic dysregulation.
Collapse
Affiliation(s)
- Julia Sánchez-Ceinos
- Department of Cell Biology, Physiology, and Immunology; Maimónides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital; Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN); Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain
| | - Oriol A Rangel-Zuñiga
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN); Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.,Lipids and Atherosclerosis Unit; Department of Internal Medicine, IMIBIC/Reina Sofia University Hospital/University of Córdoba; Avda. Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - Mercedes Clemente-Postigo
- Department of Cell Biology, Physiology, and Immunology; Maimónides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital; Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain
| | - Alicia Podadera-Herreros
- Department of Cell Biology, Physiology, and Immunology; Maimónides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital; Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN); Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain
| | - Antonio Camargo
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN); Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.,Lipids and Atherosclerosis Unit; Department of Internal Medicine, IMIBIC/Reina Sofia University Hospital/University of Córdoba; Avda. Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - Juan Francisco Alcalá-Diaz
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN); Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.,Lipids and Atherosclerosis Unit; Department of Internal Medicine, IMIBIC/Reina Sofia University Hospital/University of Córdoba; Avda. Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - Rocío Guzmán-Ruiz
- Department of Cell Biology, Physiology, and Immunology; Maimónides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital; Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN); Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain
| | - José López-Miranda
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN); Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.,Lipids and Atherosclerosis Unit; Department of Internal Medicine, IMIBIC/Reina Sofia University Hospital/University of Córdoba; Avda. Menéndez Pidal s/n, 14004, Córdoba, Spain
| | - María M Malagón
- Department of Cell Biology, Physiology, and Immunology; Maimónides Biomedical Research Institute of Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital; Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN); Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain
| |
Collapse
|
7
|
Martin-Nuñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Front Endocrinol (Lausanne) 2021; 12:639856. [PMID: 34220702 PMCID: PMC8247771 DOI: 10.3389/fendo.2021.639856] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 05/17/2021] [Indexed: 12/14/2022] Open
Abstract
Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. Although the majority of infected individuals remain asymptomatic, this bacterium colonizes the gastric mucosa causing the development of various clinical conditions as peptic ulcers, chronic gastritis and gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas, but complications are not limited to gastric ones. Extradigestive pathologies, including metabolic disturbances such as diabetes, obesity and nonalcoholic fatty liver disease, have also been associated with H. pylori infection. However, the underlying mechanisms connecting H. pylori with extragastric metabolic diseases needs to be clarified. Notably, the latest studies on the topic have confirmed that H. pylori infection modulates gut microbiota in humans. Damage in the gut bacterial community (dysbiosis) has been widely related to metabolic dysregulation by affecting adiposity, host energy balance, carbohydrate metabolism, and hormonal modulation, among others. Taking into account that Type 2 diabetic patients are more prone to be H. pylori positive, gut microbiota emerges as putative key factor responsible for this interaction. In this regard, the therapy of choice for H. pylori eradication, based on proton pump inhibitor combined with two or more antibiotics, also alters gut microbiota composition, but consequences on metabolic health of the patients has been scarcely explored. Recent studies from our group showed that, despite decreasing gut bacterial diversity, conventional H. pylori eradication therapy is related to positive changes in glucose and lipid profiles. The mechanistic insights explaining these effects should also be addressed in future research. This review will deal with the role of gut microbiota as the linking factor between H. pylori infection and metabolic diseases, and discussed the impact that gut bacterial modulation by H. pylori eradication treatment can also have in host's metabolism. For this purpose, new evidence from the latest human studies published in more recent years will be analyzed.
Collapse
Affiliation(s)
- Gracia M. Martin-Nuñez
- Unidad de Gestión Clínica de Endocrinología y Nutrición (Hospital Universitario Virgen de la Victoria), Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Isabel Cornejo-Pareja
- Unidad de Gestión Clínica de Endocrinología y Nutrición (Hospital Universitario Virgen de la Victoria), Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Mercedes Clemente-Postigo
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Department of Cell Biology, Physiology and Immunology. Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain
- *Correspondence: Francisco J. Tinahones, ; Mercedes Clemente-Postigo,
| | - Francisco J. Tinahones
- Unidad de Gestión Clínica de Endocrinología y Nutrición (Hospital Universitario Virgen de la Victoria), Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- *Correspondence: Francisco J. Tinahones, ; Mercedes Clemente-Postigo,
| |
Collapse
|
8
|
Martín-Núñez GM, Cornejo-Pareja I, Roca-Rodríguez MDM, Clemente-Postigo M, Cardona F, Fernández-García JC, Moreno-Indias I, Tinahones FJ. H. pylori Eradication Treatment Causes Alterations in the Gut Microbiota and Blood Lipid Levels. Front Med (Lausanne) 2020; 7:417. [PMID: 32850910 PMCID: PMC7431686 DOI: 10.3389/fmed.2020.00417] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Accepted: 06/30/2020] [Indexed: 12/12/2022] Open
Abstract
Background: The gut microbiome plays an important role in the lipid metabolism. Antibiotic treatment causes changes in the intestinal microbiota. Our objective was to explore the relationship between changes in the intestinal microbiota and the level of plasma high density lipoprotein cholesterol (HDL) and low density lipoprotein cholesterol (LDL). Methods: Prospective case-control study with Helicobacter pylori-positive patients undergoing eradication therapy with omeprazole, clarithromycin, and amoxicillin. Stool and blood samples were obtained from 20 controls (H. pylori negative) and 40 patients before and 2 months after antibiotic treatment. Gut microbiota was determined through 16S rRNA amplicon sequencing (Illumina MiSeq). Results: Eradication treatment for H. pylori increased the HDL levels, and caused changes in gut microbiota profiles. An unfavorable lipid profiles (high LDL and low HDL levels) was associated with a low microbial richness and an increase of the Bacteroidetes phylum. Prevotella copri, Lachonobacterium, and Delsufovibrio were positively associated with HDL while Rikenellaceae was negatively associated with HDL after completing antibiotic treatment. Conclusions:Helicobacter pylori eradication treatment could improve lipid metabolism in relation with an increase in the HDL. Changes in the abundance of specific bacteria, such as P. copri, Lachonobacterium, Delsufovibrio, and Rikenellaceae could be associated with change in the plasma HDL levels.
Collapse
Affiliation(s)
- Gracia M Martín-Núñez
- Unidad de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Isabel Cornejo-Pareja
- Unidad de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Mercedes Clemente-Postigo
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.,Departamento de Biología Celular, Fisiología e Inmunología, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - Fernando Cardona
- Unidad de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - José C Fernández-García
- Unidad de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Isabel Moreno-Indias
- Unidad de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Francisco J Tinahones
- Unidad de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
9
|
Boughanem H, Cabrera-Mulero A, Hernández-Alonso P, Clemente-Postigo M, Casanueva FF, Tinahones FJ, Morcillo S, Crujeiras AB, Macias-Gonzalez M. Association between variation of circulating 25-OH vitamin D and methylation of secreted frizzled-related protein 2 in colorectal cancer. Clin Epigenetics 2020; 12:83. [PMID: 32517740 PMCID: PMC7285750 DOI: 10.1186/s13148-020-00875-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Accepted: 05/26/2020] [Indexed: 01/06/2023] Open
Abstract
BACKGROUNDS Colorectal cancer (CRC) results from the accumulation of epigenetic and genetic changes in colon cells during neoplasic transformation, which the activation of Wingless (Wnt) signaling pathway is a common mechanism for CRC initiation. The Wnt pathway is mainly regulated by Wnt antagonists, as secreted frizzled-related protein (SFRP) family. Indeed, SFRP2 is proposed as a noninvasive biomarker for CRC diagnosis. Vitamin D also antagonizes Wnt signaling in colon cancers cells. Several studies showed that vitamin D was able to alter DNA methylation, although this mechanism is not yet clear. Therefore, the aim of this study was to find an association between circulating 25-OH vitamin D (30th percentile of vitamin D) and the SFRP2 methylation. METHODS A total of 67 CRC patients were included in the study. These patients were subdivided into two groups based on their 30th percentile vitamin D (20 patients were below, and 47 participants were above the 30th percentile of vitamin D). We investigated the SFRP2 methylation in peripheral blood mononuclear cells (PBMCs), visceral adipose tissue (VAT), CRC tumor tissue, and adjacent tumor-free area. We also determined the relationship between SFRP2 methylation and methylation of carcinogenic and adipogenic genes. Finally, we tested the effect of vitamin D on the SFRP2 methylation in human colorectal carcinoma cell lines 116 (HCT116) and studied the association of neoadjuvant therapy under the 30th percentile vitamin D with SFRP2 promoter methylation. RESULTS SFRP2 methylation in tumor area was decreased in patients who had higher levels of vitamin D. SFRP2 promoter methylation was positively correlated in tumor area with insulin and homeostasis model assessment of insulin resistance (HOMA-IR) but negatively correlated with HDL-c. SFRP2 methylation was also correlated with T cell lymphoma invasion and metastasis 1 (TIAM1) methylation in tumor area and CCAAT/enhancer-binding protein alpha (C/EBPα) in VAT. Treatment with vitamin D did not affect SFRP2 methylation in HCT116 cell line. Finally, neoadjuvant treatment was correlated with higher circulating 25-OH vitamin D and SFRP2 methylation under linear regression model. CONCLUSION Our results showed that higher circulating vitamin D is associated with low SFRP2 promoter methylation. Therefore, our results could suggest that vitamin D may have an epigenetic effect on DNA methylation. Finally, higher vitamin D could contribute to an improvement response to neoadjuvant treatment.
Collapse
Affiliation(s)
- Hatim Boughanem
- Biomedical Research Institute of Malaga (IBIMA), Faculty of Science, University of Malaga, 29010, Málaga, Spain
- Deparment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Malaga (IBIMA) and University of Malaga, Malaga, Spain
| | - Amanda Cabrera-Mulero
- Deparment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Malaga (IBIMA) and University of Malaga, Malaga, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain
| | - Pablo Hernández-Alonso
- Deparment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Malaga (IBIMA) and University of Malaga, Malaga, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain
- Human Nutrition Unit, Faculty of Medicine and Health Sciences, Sant Joan Hospital, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201, Reus, Spain
| | - Mercedes Clemente-Postigo
- Deparment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Malaga (IBIMA) and University of Malaga, Malaga, Spain
- Department of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain
| | - Felipe F Casanueva
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain
- Epigenomics in Endocrinology and Nutrition Group, Instituto de Investigación Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS/SERGAS), Santiago de Compostela, Spain
| | - Francisco José Tinahones
- Deparment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Malaga (IBIMA) and University of Malaga, Malaga, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain
| | - Sonsoles Morcillo
- Deparment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Malaga (IBIMA) and University of Malaga, Malaga, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain
| | - Ana B Crujeiras
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain.
- Epigenomics in Endocrinology and Nutrition Group, Instituto de Investigación Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.
| | - Manuel Macias-Gonzalez
- Deparment of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Malaga (IBIMA) and University of Malaga, Malaga, Spain.
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain.
| |
Collapse
|
10
|
Clemente-Postigo M, Tinahones A, El Bekay R, Malagón MM, Tinahones FJ. The Role of Autophagy in White Adipose Tissue Function: Implications for Metabolic Health. Metabolites 2020; 10:metabo10050179. [PMID: 32365782 PMCID: PMC7281383 DOI: 10.3390/metabo10050179] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2020] [Revised: 04/27/2020] [Accepted: 04/28/2020] [Indexed: 02/07/2023] Open
Abstract
White adipose tissue (WAT) is a highly adaptive endocrine organ that continuously remodels in response to nutritional cues. WAT expands to store excess energy by increasing adipocyte number and/or size. Failure in WAT expansion has serious consequences on metabolic health resulting in altered lipid, glucose, and inflammatory profiles. Besides an impaired adipogenesis, fibrosis and low-grade inflammation also characterize dysfunctional WAT. Nevertheless, the precise mechanisms leading to impaired WAT expansibility are yet unresolved. Autophagy is a conserved and essential process for cellular homeostasis, which constitutively allows the recycling of damaged or long-lived proteins and organelles, but is also highly induced under stress conditions to provide nutrients and remove pathogens. By modulating protein and organelle content, autophagy is also essential for cell remodeling, maintenance, and survival. In this line, autophagy has been involved in many processes affected during WAT maladaptation, including adipogenesis, adipocyte, and macrophage function, inflammatory response, and fibrosis. WAT autophagy dysregulation is related to obesity and diabetes. However, it remains unclear whether WAT autophagy alteration in obese and diabetic patients are the cause or the consequence of WAT malfunction. In this review, current data regarding these issues are discussed, focusing on evidence from human studies.
Collapse
Affiliation(s)
- Mercedes Clemente-Postigo
- Department of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Reina Sofia University Hospital, University of Cordoba, Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain;
- Correspondence: (M.C.-P.); (F.J.T.); Tel.: +34-957213728 (M.C.-P.); +34-951032648 (F.J.T.)
| | - Alberto Tinahones
- Unidad de Gestión Clínica de Endocrinología y Nutrición (Hospital Universitario Virgen de la Victoria), Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Campus Teatinos s/n, 29010 Málaga, Spain;
| | - Rajaa El Bekay
- Unidad de Gestión Clínica de Endocrinología y Nutrición (Hospital Universitario Regional de Málaga), Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Campus Teatinos s/n, 29010 Málaga, Spain;
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
| | - María M. Malagón
- Department of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Reina Sofia University Hospital, University of Cordoba, Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain;
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
| | - Francisco J. Tinahones
- Unidad de Gestión Clínica de Endocrinología y Nutrición (Hospital Universitario Virgen de la Victoria), Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Campus Teatinos s/n, 29010 Málaga, Spain;
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
- Correspondence: (M.C.-P.); (F.J.T.); Tel.: +34-957213728 (M.C.-P.); +34-951032648 (F.J.T.)
| |
Collapse
|
11
|
Martín-Núñez GM, Cornejo-Pareja I, Coin-Aragüez L, Roca-Rodríguez MDM, Muñoz-Garach A, Clemente-Postigo M, Cardona F, Moreno-Indias I, Tinahones FJ. H. pylori eradication with antibiotic treatment causes changes in glucose homeostasis related to modifications in the gut microbiota. PLoS One 2019; 14:e0213548. [PMID: 30870471 PMCID: PMC6417676 DOI: 10.1371/journal.pone.0213548] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Accepted: 02/22/2019] [Indexed: 12/15/2022] Open
Abstract
Background H. pylori infection and eradication cause perturbations of the gut microbiome. The gut microbiota has been identified as a potential contributor to metabolic diseases. We evaluate whether these alterations in intestinal microbiota composition produced by H. pylori infection and its posterior eradication with antibiotic treatment could be associated with glucose homeostasis in metabolically healthy subjects. Methods Forty adult patients infected with H. pylori and 20 control subjects were recruited. The infected subjects were evaluated before and two months after eradication treatment (omeprazole, clarithromycin, amoxicillin). The microbiota composition in fecal samples was determined by 16S rRNA gene (V3-V4) sequencing using Illumina Miseq. Results Patients (pre- and post-H. pylori eradication) showed a decreased bacterial richness and diversity with respect to controls. There was an improvement in glucose homeostasis in subjects two months after H. pylori eradication treatment. Changes in the amount of Rikenellaceae, Butyricimonas, E. biforme, B. fragilis, and Megamonas were inversely associated with changes in the glucose level or related parameters (Hb1ac) in H. pylori eradication subjects. Conclusions H. pylori infection and eradication with antibiotic treatment causes alteration of the human gut microbiome. The increase in SCFA-producing bacteria and glucose-removing bacteria, specifically members of Megamonas, Rikenellaceae and Butyricimonas, has been related with an improvement in glucose homeostasis after H. pylori eradication with antibiotic treatment.
Collapse
Affiliation(s)
- Gracia Mª Martín-Núñez
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Isabel Cornejo-Pareja
- Departamento de Endocrinología y Nutrición, Hospital Virgen de la Victoria, Málaga, Spain
| | - Leticia Coin-Aragüez
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Araceli Muñoz-Garach
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
- Departamento de Endocrinología y Nutrición, Hospital Virgen de la Victoria, Málaga, Spain
| | - Mercedes Clemente-Postigo
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Fernando Cardona
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Isabel Moreno-Indias
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Francisco J Tinahones
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
12
|
Gentile AM, Lhamyani S, Coín-Aragüez L, Clemente-Postigo M, Oliva Olivera W, Romero-Zerbo SY, García-Serrano S, García-Escobar E, Zayed H, Doblado E, Bermúdez-Silva FJ, Murri M, Tinahones FJ, El Bekay R. miR-20b, miR-296, and Let-7f Expression in Human Adipose Tissue is Related to Obesity and Type 2 Diabetes. Obesity (Silver Spring) 2019; 27:245-254. [PMID: 30597763 DOI: 10.1002/oby.22363] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 10/03/2018] [Indexed: 12/16/2022]
Abstract
OBJECTIVE This study aimed to analyze the potential association of different microRNA (miRNA) molecules with both type 2 diabetes (T2D) and obesity and determine their target genes. METHODS Quantitative PCR was used to analyze the miR-20b, miR-296, and Let-7f levels in human visceral and subcutaneous adipose tissues (ATs) in relation to obesity and T2D, miRTarBase 4.0 was used for validation of target genes, and the Protein Analysis Through Evolutionary Relationships (PANTHER) Classification System and the Database for Annotation, Visualization and Integrated Discovery (DAVID) were used to annotate the biological processes of the predicted targets. RESULTS In AT, miR-20b, miR-296, and Let-7f levels were significantly different between normoglycemic subjects and those with T2D. In visceral adipose tissue, miRNA levels were higher in normoglycemic/obesity samples than in T2D/obesity samples. miR-20b-miR-296 and Let-7f target genes that showed significant differences in both ATs in relation to obesity and T2D were CDKN1A, CX3CL1, HIF1A, PPP2R1B, STAT3, and VEGFA. These genes are known to be principally involved in the vascular endothelial growth factor (VEGF) and WNT pathways. CONCLUSIONS This study provides experimental evidence of the possible correlation between AT miR-20b-miR-296-Let-7f with obesity and T2D, which might involve vascular endothelial growth factor and WNT-dependent pathways that are regulated by six different genes, suggesting a novel signaling pathway that could be important for understanding the mechanisms underlying the AT dysfunction associated with obesity and T2D.
Collapse
Affiliation(s)
- Adriana-Mariel Gentile
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, Universidad de Málaga, Campus Teatinos s/n - 29010, Málaga, Spain
| | - Said Lhamyani
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, Universidad de Málaga, Campus Teatinos s/n - 29010, Málaga, Spain
| | - Leticia Coín-Aragüez
- Unidad de Gestión Clinica de Endocrinologia y Nutricion, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Málaga, Spain
| | - Mercedes Clemente-Postigo
- Unidad de Gestión Clinica de Endocrinologia y Nutricion, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Málaga, Spain
| | - Wilfredo Oliva Olivera
- Unidad de Gestión Clinica de Endocrinologia y Nutricion, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Málaga, Spain
| | - Silvana-Yanina Romero-Zerbo
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Málaga, Spain
| | - Sara García-Serrano
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Málaga, Spain
| | - Eva García-Escobar
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Málaga, Spain
| | - Hatem Zayed
- Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar
| | - Esther Doblado
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, Universidad de Málaga, Campus Teatinos s/n - 29010, Málaga, Spain
| | - Francisco-Javier Bermúdez-Silva
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Málaga, Spain
| | - Mora Murri
- Unidad de Gestión Clinica de Endocrinologia y Nutricion, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Málaga, Spain
| | - Francisco J Tinahones
- Unidad de Gestión Clinica de Endocrinologia y Nutricion, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Málaga, Spain
| | - Rajaa El Bekay
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Institute of Health Carlos III, Málaga, Spain
| |
Collapse
|
13
|
Clemente-Postigo M, Oliva-Olivera W, Coin-Aragüez L, Ramos-Molina B, Giraldez-Perez RM, Lhamyani S, Alcaide-Torres J, Perez-Martinez P, El Bekay R, Cardona F, Tinahones FJ. Metabolic endotoxemia promotes adipose dysfunction and inflammation in human obesity. Am J Physiol Endocrinol Metab 2019; 316:E319-E332. [PMID: 30422702 DOI: 10.1152/ajpendo.00277.2018] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Impaired adipose tissue (AT) lipid handling and inflammation is associated with obesity-related metabolic diseases. Circulating lipopolysaccharides (LPSs) from gut microbiota (metabolic endotoxemia), proposed as a triggering factor for the low-grade inflammation in obesity, might also be responsible for AT dysfunction. Nevertheless, this hypothesis has not been explored in human obesity. To analyze the relationship between metabolic endotoxemia and AT markers for lipogenesis, lipid handling, and inflammation in human obesity, 33 patients with obesity scheduled for surgery were recruited and classified according to their LPS levels. Visceral and subcutaneous AT gene and protein expression were analyzed and adipocyte and AT in vitro assays performed. Subjects with obesity with a high degree of metabolic endotoxemia had lower expression of key genes for AT function and lipogenesis ( SREBP1, FABP4, FASN, and LEP) but higher expression of inflammatory genes in visceral and subcutaneous AT than subjects with low LPS levels. In vitro experiments corroborated that LPS are responsible for adipocyte and AT inflammation and downregulation of PPARG, SCD, FABP4, and LEP expression and LEP secretion. Thus, metabolic endotoxemia influences AT physiology in human obesity by decreasing the expression of factors involved in AT lipid handling and function as well as by increasing inflammation.
Collapse
Affiliation(s)
- Mercedes Clemente-Postigo
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria/Universidad de Málaga. Málaga, Spain
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
| | - Wilfredo Oliva-Olivera
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria/Universidad de Málaga. Málaga, Spain
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
| | - Leticia Coin-Aragüez
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria/Universidad de Málaga. Málaga, Spain
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
| | - Bruno Ramos-Molina
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria/Universidad de Málaga. Málaga, Spain
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
| | - Rosa María Giraldez-Perez
- Departamento Biología Celular, Genética y Fisiología, Facultad de Ciencias. Universidad de Málaga , Spain
| | - Said Lhamyani
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario/Universidad de Málaga , Málaga , Spain
| | - Juan Alcaide-Torres
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria/Universidad de Málaga. Málaga, Spain
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
| | - Pablo Perez-Martinez
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
- Lipid and Atherosclerosis Research Unit, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain
| | - Rajaa El Bekay
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario/Universidad de Málaga , Málaga , Spain
| | - Fernando Cardona
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria/Universidad de Málaga. Málaga, Spain
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
| | - Francisco J Tinahones
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria/Universidad de Málaga. Málaga, Spain
- Centro de Investigación Biomédica En Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII) , Málaga , Spain
| |
Collapse
|
14
|
Abstract
Obesity is one of the most serious worldwide epidemics of the twenty-first century according to the World Health Organization. Frequently associated with a number of comorbidities, obesity threatens and compromises individual health and quality of life. Bariatric surgery (BS) has been demonstrated to be an effective treatment to achieve not only sustained weight loss but also significant metabolic improvement that goes beyond mere weight loss. The beneficial effects of BS on metabolic traits are so widely recognized that some authors have proposed BS as metabolic surgery that could be prescribed even for moderate obesity. However, most of the BS procedures imply malabsorption and/or gastric acid reduction which lead to nutrient deficiency and, consequently, further complications could be developed in the long term. In fact, BS not only affects metabolic homeostasis but also has pronounced effects on endocrine systems other than those exclusively involved in metabolic function. The somatotropic, corticotropic, and gonadal axes as well as bone health have also been shown to be affected by the various BS procedures. Accordingly, further consequences and complications of BS in the long term in systems other than metabolic system need to be addressed in large cohorts, taking into account each bariatric procedure before making generalized recommendations for BS. In this review, current data regarding these issues are summarized, paying special attention to the somatotropic, corticotropic, gonadal axes, and bone post-operative health.
Collapse
Affiliation(s)
- Isabel Cornejo-Pareja
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga—IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain
| | - Mercedes Clemente-Postigo
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga—IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain
- *Correspondence: Mercedes Clemente-Postigo
| | - Francisco J. Tinahones
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga—IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
- Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain
- Francisco J. Tinahones
| |
Collapse
|
15
|
|
16
|
Surendran RP, Udayyapan SD, Clemente-Postigo M, Havik SR, Schimmel AWM, Tinahones F, Nieuwdorp M, Dallinga-Thie GM. Decreased GPIHBP1 protein levels in visceral adipose tissue partly underlie the hypertriglyceridemic phenotype in insulin resistance. PLoS One 2018; 13:e0205858. [PMID: 30408040 PMCID: PMC6224034 DOI: 10.1371/journal.pone.0205858] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 10/02/2018] [Indexed: 01/29/2023] Open
Abstract
GPIHBP1 is a protein localized at the endothelial cell surface that facilitates triglyceride (TG) lipolysis by binding lipoprotein lipase (LPL). Whether Glycosyl Phosphatidyl Inositol high density lipoprotein binding protein 1 (GPIHBP1) function is impaired and may underlie the hyperTG phenotype observed in type 2 diabetes is not yet established. To elucidate the mechanism underlying impaired TG homeostasis in insulin resistance state we studied the effect of insulin on GPIHBP1 protein expression in human microvascular endothelial cells (HMVEC) under flow conditions. Next, we assessed visceral adipose tissue GPIHBP1 protein expression in type 2 diabetes Leprdb/db mouse model as well as in subjects with ranging levels of insulin resistance. We report that insulin reduces the expression of GPIHBP1 protein in HMVECs. Furthermore, GPIHBP1 protein expression in visceral adipose tissue in Leprdb/db mice is significantly reduced as is the active monomeric form of GPIHBP1 as compared to Leprdb/m mice. A similar decrease in GPIHBP1 protein was observed in subjects with increased body weight. GPIHBP1 protein expression was negatively associated with insulin and HOMA-IR. In conclusion, our data suggest that decreased GPIHBP1 availability in insulin resistant state may hamper peripheral lipolysis capacity.
Collapse
Affiliation(s)
- R. Preethi Surendran
- Department of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands
| | - Shanti D. Udayyapan
- Department of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands
| | - Mercedes Clemente-Postigo
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Malaga, Malaga, Spain
- CIBER Fisiopatologia de la Obesidad y Nutrición (CB06/03), Barcelona, Spain
| | - Stefan R. Havik
- Department of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands
| | - Alinda W. M. Schimmel
- Department of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands
| | - Fransisco Tinahones
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Malaga, Malaga, Spain
- CIBER Fisiopatologia de la Obesidad y Nutrición (CB06/03), Barcelona, Spain
| | - Max Nieuwdorp
- Department of Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands
| | - Geesje M. Dallinga-Thie
- Department of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands
- Unidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Malaga, Malaga, Spain
- * E-mail:
| |
Collapse
|
17
|
Castellano-Castillo D, Moreno-Indias I, Fernandez-Garcia JC, Clemente-Postigo M, Castro-Cabezas M, Tinahones FJ, Queipo-Ortuño MI, Cardona F. Complement Factor C3 Methylation and mRNA Expression Is Associated to BMI and Insulin Resistance in Obesity. Genes (Basel) 2018; 9:E410. [PMID: 30104553 PMCID: PMC6116013 DOI: 10.3390/genes9080410] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 07/20/2018] [Accepted: 08/08/2018] [Indexed: 12/24/2022] Open
Abstract
Epigenetic marks, and especially DNA methylation, are becoming an important factor in obesity, which could help to explain its etiology and associated comorbidities. Adipose tissue, now considered as an important endocrine organ, produces complement system factors. Complement component 3 (C3) turns out to be an important protein in metabolic disorders, via either inflammation or the C3 subproduct acylation stimulating protein (ASP) which directly stimulates lipid storage. In this study, we analyze C3 DNA methylation in adipose tissue from subjects with a different grade of obesity. Adipose tissue samples were collected from subjects with a different degree of obesity determined by their body mass index (BMI) as: Overweight subjects (BMI ≥ 25 and <30), obese class 1/2 subjects (BMI ≥ 30 and <40) and obese class 3 subjects (BMI ≥ 40). C3 DNA methylation was measured for 7 CpGs by pyrosequencition using the Pyromark technology (Qiagen, Madrid Spain). C3 messenger RNA (mRNA) levels were analyzed by pre-designed Taqman assays (Applied biosystems, Foster City, CA, USA) and ASP/C3a was measured using a ELISA kit. The data were analyzed using the statistic package SPSS. C3 DNA methylation levels were lower in the morbid obese group. Accordingly, C3 methylation correlated negatively with BMI and leptin. However, C3 mRNA levels were more associated with insulin resistance, and positive correlations with insulin, glucose and homeostasis model assessment-estimated insulin resistance (HOMA-IR) existed. ASP correlated negatively with high density lipoprotein (HDL) cholesterol. C3 methylation levels were associated to adiposity variables, such as BMI and leptin, while the C3 mRNA levels were associated to glucose metabolism.
Collapse
Affiliation(s)
- Daniel Castellano-Castillo
- Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, 29010 Malaga, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBERobn), 28029 Madrid, Spain.
| | - Isabel Moreno-Indias
- Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, 29010 Malaga, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBERobn), 28029 Madrid, Spain.
| | - Jose Carlos Fernandez-Garcia
- Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, 29010 Malaga, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBERobn), 28029 Madrid, Spain.
| | - Mercedes Clemente-Postigo
- Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, 29010 Malaga, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBERobn), 28029 Madrid, Spain.
| | - Manuel Castro-Cabezas
- Department of Internal Medicine Center for Endocrinology, Diabetes and Vascular Medicine St. Franciscus Gasthuis Hospital, 3045 PM Rotterdam, The Netherlands.
| | - Francisco José Tinahones
- Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, 29010 Malaga, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBERobn), 28029 Madrid, Spain.
| | - María Isabel Queipo-Ortuño
- Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, 29010 Malaga, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBERobn), 28029 Madrid, Spain.
| | - Fernando Cardona
- Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, 29010 Malaga, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBERobn), 28029 Madrid, Spain.
| |
Collapse
|
18
|
Castellano-Castillo D, Morcillo S, Clemente-Postigo M, Crujeiras AB, Fernandez-García JC, Torres E, Tinahones FJ, Macias-Gonzalez M. Adipose tissue inflammation and VDR expression and methylation in colorectal cancer. Clin Epigenetics 2018; 10:60. [PMID: 29719581 PMCID: PMC5921388 DOI: 10.1186/s13148-018-0493-0] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Accepted: 04/12/2018] [Indexed: 12/16/2022] Open
Abstract
Background Lack of vitamin D (VD) has been associated with colorectal cancer (CRC). VD has anti-inflammatory effects and regulates several cellular pathways by means of its receptor, including epigenetic modifications. Adipose tissue dysfunction has been related to low-grade inflammation, which is related to diseases like cancer. The aim of this study was to explore the relationship between serum 25-hydroxyvitamin D (25(OH)D), adipose tissue gene expression of VD receptor (VDR), pro-inflammatory markers, and the epigenetic factor DNA methyltransferase 3a (DNMT3A) as well as VDR promoter methylation in CRC. Methods Blood and visceral adipose tissue from 57 CRC and 50 healthy control subjects were collected. CRC subjects had lower serum 25(OH)D levels and higher VDR gene expression, and these were negatively correlated in the CRC group. Results Adipose tissue NFκB1, IL6, and IL1B gene expression were higher in the CRC subjects than in the control subjects. 25(OH)D correlated negatively with NFκB1 and CRP. In turn, CRP correlated positively with NFκB1, IL6, IL1B, and VDR gene expression as well as NFκB1 that correlated positively with IL6 and IL1B. DNMT3A mRNA was negatively correlated with serum 25(OH)D and positively correlated with VDR DNA methylation. VDR DNA methylation at position 4 had lower levels in the CRC group. Global NFκB1 methylation at dinucleotide 3 was lower in the CRC group. Conclusion Our results suggest that adipose tissue may be a key factor in CRC development. The low 25(OH)D levels and high adipose tissue VDR expression in CRC may, at least in part, mediate this relationship by modifying adipose tissue DNA methylation and promoting inflammation. Electronic supplementary material The online version of this article (10.1186/s13148-018-0493-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Daniel Castellano-Castillo
- 11Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
| | - Sonsoles Morcillo
- 2CIBER Fisiopatología de la Obesidad y Nutrición (CB06/03), Madrid, Spain
| | - Mercedes Clemente-Postigo
- 11Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain.,2CIBER Fisiopatología de la Obesidad y Nutrición (CB06/03), Madrid, Spain
| | - Ana Belén Crujeiras
- 3Laboratory of Molecular and Cellular Endocrinology, Instituto de Investigación Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS/SERGAS), Santiago de Compostela University (USC), Santiago de Compostela, Spain.,4CIBER Fisiopatología de la Obesidad y la Nutrición (CIBERobn), Madrid, Spain
| | - Jose Carlos Fernandez-García
- 11Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain.,2CIBER Fisiopatología de la Obesidad y Nutrición (CB06/03), Madrid, Spain
| | - Esperanza Torres
- 5Unidad de Gestión Clínica de Oncología Intercentros Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - Francisco José Tinahones
- 11Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain.,2CIBER Fisiopatología de la Obesidad y Nutrición (CB06/03), Madrid, Spain
| | - Manuel Macias-Gonzalez
- 11Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain.,2CIBER Fisiopatología de la Obesidad y Nutrición (CB06/03), Madrid, Spain
| |
Collapse
|
19
|
Moreno-Indias I, Tinahones FJ, Clemente-Postigo M, Castellano-Castillo D, Fernández-García JC, Macias-Gonzalez M, Queipo-Ortuño MI, Cardona F. Molecular effect of fenofibrate on PBMC gene transcription related to lipid metabolism in patients with metabolic syndrome. Clin Endocrinol (Oxf) 2017; 86:784-790. [PMID: 28251701 DOI: 10.1111/cen.13320] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 02/08/2017] [Accepted: 02/25/2017] [Indexed: 01/21/2023]
Abstract
BACKGROUND Both fasting and postprandial hypertriglyceridaemia are considered independent risk factors for atherosclerosis. Treatment of hypertriglyceridaemia is based on fibrates, which activate the peroxisome proliferator-activated receptor alpha (PPARα). However, the metabolic pathways that activate or inhibit fibrates, and how the postprandial triglyceride levels are modified, have not yet been fully described. Accordingly, the aim of this study was to determine the feasibility of peripheral blood mononuclear cells (PBMC) to study the effects of fenofibrate in patients with the metabolic syndrome. MATERIALS AND METHODS A fat overload was given to 50 patients before and after treatment with fenofibrate for 3 months. Anthropometric and biochemical variables as well as gene expression in PBMC were analysed. RESULTS After treatment with fenofibrate, we observed a decrease in both baseline and postprandial (3 h after the fat overload) levels of serum triglycerides, cholesterol and uric acid and an increase in HDL cholesterol and apolipoprotein AI levels. After treatment, there was also a rise in PPARα and RXRα expression and changes in genes regulated by PPARα, both baseline and postprandial. Furthermore, in vitro experiments showed that a PPARα agonist changed the expression of genes related with lipid metabolism. CONCLUSION Treatment with fenofibrate reduced fasting and postprandial serum triglyceride levels, possibly through a mechanism related with an increase in the expression of RXRα and PPARα, by activating the pathways involved in the uptake and degradation of triglycerides and increasing the synthesis of apolipoprotein. These results suggest that PBMC may be useful for the easy study of fenofibrate actions.
Collapse
Affiliation(s)
- I Moreno-Indias
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, Spain
- Unidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Hospital Clinico Universitario Virgen de la Victoria, Universidad de Malaga, Malaga, Spain
| | - F J Tinahones
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, Spain
- Unidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Hospital Clinico Universitario Virgen de la Victoria, Universidad de Malaga, Malaga, Spain
| | - M Clemente-Postigo
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, Spain
- Unidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Hospital Clinico Universitario Virgen de la Victoria, Universidad de Malaga, Malaga, Spain
| | - D Castellano-Castillo
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, Spain
- Unidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Hospital Clinico Universitario Virgen de la Victoria, Universidad de Malaga, Malaga, Spain
| | - J C Fernández-García
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, Spain
- Unidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Hospital Clinico Universitario Virgen de la Victoria, Universidad de Malaga, Malaga, Spain
| | - M Macias-Gonzalez
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, Spain
- Unidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Hospital Clinico Universitario Virgen de la Victoria, Universidad de Malaga, Malaga, Spain
| | - M I Queipo-Ortuño
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, Spain
- Unidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Hospital Clinico Universitario Virgen de la Victoria, Universidad de Malaga, Malaga, Spain
| | - F Cardona
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, Spain
- Unidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain
- Hospital Clinico Universitario Virgen de la Victoria, Universidad de Malaga, Malaga, Spain
| |
Collapse
|
20
|
Oliva-Olivera W, Coín-Aragüez L, Lhamyani S, Clemente-Postigo M, Torres JA, Bernal-López MR, El Bekay R, Tinahones FJ. Adipogenic Impairment of Adipose Tissue-Derived Mesenchymal Stem Cells in Subjects With Metabolic Syndrome: Possible Protective Role of FGF2. J Clin Endocrinol Metab 2017; 102:478-487. [PMID: 27967316 DOI: 10.1210/jc.2016-2256] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Accepted: 12/08/2016] [Indexed: 11/19/2022]
Abstract
CONTEXT The decreased expansion capacity of adipose tissue plays a crucial role in the onset of disorders associated with metabolic syndrome. OBJECTIVE The aim of this study was to examine the state of adipose tissue-derived mesenchymal stem cells (ASCs) from obese subjects with different metabolic profiles. DESIGN This was a 2-year study to enroll subjects who underwent bariatric surgery or cholecystectomy. SETTING University Hospital. PATIENTS AND INTERVENTION Patients who underwent either bariatric surgery (20 morbidly obese) or cholecystectomy (40 subjects) participated in the study. MAIN OUTCOME MEASURES ASCs were obtained from both visceral and subcutaneous adipose tissue. Adipogenic, fibrotic gene expression was quantified by quantitative polymerase chain reaction; Smad7 and fibroblast growth factor 2 were quantified by western blotting and enzyme-linked immunosorbent assay, respectively. The susceptibility of ASCs to apoptosis, their population doubling time, and their clonogenic potential were evaluated. RESULTS The worsening metabolic profile of the patients was accompanied by a decrease in the intrinsic levels of adipogenic gene expression, reduced proliferation rate, clonogenic potential, and exportation of fibroblast growth factor 2 to the cell surface of the ASCs derived from both tissues. In addition, the ASCs from patients without metabolic syndrome showed differences in susceptibility to apoptosis and expression of TGFβ-signaling inhibitory protein Smad7 with respect to the ASCs from patients with metabolic syndrome. CONCLUSION Our results suggest that the decrease in adipogenic-gene mRNA and clonogenic potential, as well as the accumulation of fibrotic proteins with metabolic alterations, could be a relevant mechanism controlling the number and size of neogenerated adipocytes and involved in alteration of adipose-tissue expansion.
Collapse
Affiliation(s)
- Wilfredo Oliva-Olivera
- Departments of Clinical Endocrinology and Nutrition, and
- CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Leticia Coín-Aragüez
- Departments of Clinical Endocrinology and Nutrition, and
- CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Said Lhamyani
- Departments of Clinical Endocrinology and Nutrition, and
- CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Mercedes Clemente-Postigo
- Departments of Clinical Endocrinology and Nutrition, and
- CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Juan Alcaide Torres
- Departments of Clinical Endocrinology and Nutrition, and
- CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Maria Rosa Bernal-López
- Internal Medicine, Regional University Hospital of Málaga, Institute of Biomedical Research of Málaga, Hospital of Málaga (Virgen de la Victoria), University of Málaga, Málaga 29010, Spain; and
- CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Rajaa El Bekay
- Departments of Clinical Endocrinology and Nutrition, and
- CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Francisco José Tinahones
- Departments of Clinical Endocrinology and Nutrition, and
- CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid 28029, Spain
| |
Collapse
|
21
|
Marchal-Escalona C, Herrera-Imbroda B, Clemente-Postigo M, Alcaide-Torres J, Quiñonero A, Marchal M, Queipo-Ortuño MI, Aragón IM, Martín-Morales A, Lara MF, Cardona F. PDE5A Polymorphisms Influence on Sildenafil Treatment Success. J Sex Med 2016; 13:1104-10. [DOI: 10.1016/j.jsxm.2016.04.075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Revised: 04/22/2016] [Accepted: 04/26/2016] [Indexed: 10/21/2022]
|
22
|
El Bekay R, Coín-Aragüez L, Fernández-García D, Oliva-Olivera W, Bernal-López R, Clemente-Postigo M, Delgado-Lista J, Diaz-Ruiz A, Guzman-Ruiz R, Vázquez-Martínez R, Lhamyani S, Roca-Rodríguez MM, Veledo SF, Vendrell J, Malagón MM, Tinahones FJ. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. Br J Pharmacol 2016; 173:1820-34. [PMID: 26993859 DOI: 10.1111/bph.13481] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 02/15/2016] [Accepted: 02/29/2016] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND AND PURPOSE Glucagon-like peptide-1 (GLP-1) analogues improve glycaemic control in type 2 diabetic (T2D) patients and cause weight loss in obese subjects by as yet unknown mechanisms. We recently demonstrated that the GLP-1 receptor, which is present in adipocytes and the stromal vascular fraction of human adipose tissue (AT), is up-regulated in AT of insulin-resistant morbidly obese subjects compared with healthy lean subjects. The aim of this study was to explore the effects of in vitro and in vivo administration of GLP-1 and its analogues on AT and adipocyte functions from T2D morbidly obese subjects. EXPERIMENTAL APPROACH We analysed the effects of GLP-1 on human AT and isolated adipocytes in vitro and the effects of GLP-1 mimetics on AT of morbidly obese T2D subjects in vivo. KEY RESULTS GLP-1 down-regulated the expression of lipogenic genes when administered during in vitro differentiation of human adipocytes from morbidly obese patients. GLP-1 also decreased the expression of adipogenic/lipogenic genes in AT explants and mature adipocytes, while increasing that of lipolytic markers and adiponectin. In 3T3-L1 adipocytes, GLP-1 decreased free cytosolic Ca2+ concentration ([Ca2+]i). GLP-1-induced responses were only partially blocked by GLP-1 receptor antagonist exendin (9–39). Moreover, administration of exenatide or liraglutide reduced adipogenic and inflammatory marker mRNA in AT of T2D obese subjects. CONCLUSIONS AND IMPLICATIONS Our data suggest that the beneficial effects of GLP-1 are associated with changes in the adipogenic potential and ability of AT to expand, via activation of the canonical GLP-1 receptor and an additional, as yet unknown, receptor.
Collapse
Affiliation(s)
- Rajaa El Bekay
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Laboratory of Biomedical Research, Virgen de la Victoria Clinical University Hospital, Málaga, Spain
| | - Leticia Coín-Aragüez
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Laboratory of Biomedical Research, Virgen de la Victoria Clinical University Hospital, Málaga, Spain
| | - Diego Fernández-García
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Endocrinology Service, Virgen de la Victoria Clinical University Hospital, Malaga, Spain
| | - Wilfredo Oliva-Olivera
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Laboratory of Biomedical Research, Virgen de la Victoria Clinical University Hospital, Málaga, Spain
| | - Rosa Bernal-López
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Laboratory of Biomedical Research, Virgen de la Victoria Clinical University Hospital, Málaga, Spain
| | - Mercedes Clemente-Postigo
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Laboratory of Biomedical Research, Virgen de la Victoria Clinical University Hospital, Málaga, Spain
| | - Javier Delgado-Lista
- Lipids and Atherosclerosis Unit, Department of Medicine, IMIBIC/Reina Sofia University Hospital/University of Córdoba, Córdoba, Spain
| | - Alberto Diaz-Ruiz
- Department of Cell Biology, Physiology, and Immunology, IMIBIC/Reina Sofia University Hospital/Universidad de Cordoba, CIBERobn, Córdoba, Spain
| | - Rocío Guzman-Ruiz
- Department of Cell Biology, Physiology, and Immunology, IMIBIC/Reina Sofia University Hospital/Universidad de Cordoba, CIBERobn, Córdoba, Spain
| | - Rafael Vázquez-Martínez
- Department of Cell Biology, Physiology, and Immunology, IMIBIC/Reina Sofia University Hospital/Universidad de Cordoba, CIBERobn, Córdoba, Spain
| | - Said Lhamyani
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Laboratory of Biomedical Research, Virgen de la Victoria Clinical University Hospital, Málaga, Spain
| | - María Mar Roca-Rodríguez
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Laboratory of Biomedical Research, Virgen de la Victoria Clinical University Hospital, Málaga, Spain
| | | | - Joan Vendrell
- CIBERDEM, Joan XXIII University Hospital, Pere Virgili Institute, Tarragona, Spain
| | - María M Malagón
- Department of Cell Biology, Physiology, and Immunology, IMIBIC/Reina Sofia University Hospital/Universidad de Cordoba, CIBERobn, Córdoba, Spain
| | - Francisco José Tinahones
- CIBER Pathophysiology of Obesity and Nutrition CB06/03, Carlos III Health Institute, Malaga, Spain.,Endocrinology Service, Virgen de la Victoria Clinical University Hospital, Malaga, Spain
| |
Collapse
|
23
|
Surendran R, Clemente-Postigo M, Kootte R, van Eijk M, Garrido-Sanchez L, Cardona F, Tinahones F, Nieuwdorp M, Dallinga-Thie G. Impaired insulin signalling leads to decreased expression of GPIHBP1. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
Roca-Rodríguez MM, El Bekay R, Garrido-Sanchez L, Gómez-Serrano M, Coin-Aragüez L, Oliva-Olivera W, Lhamyani S, Clemente-Postigo M, García-Santos E, de Luna Diaz R, Yubero-Serrano EM, Fernández Real JM, Peral B, Tinahones FJ. Parathyroid Hormone-Related Protein, Human Adipose-Derived Stem Cells Adipogenic Capacity and Healthy Obesity. J Clin Endocrinol Metab 2015; 100:E826-35. [PMID: 25885945 DOI: 10.1210/jc.2014-4132] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVE This study aimed to define the potential role of PTHrP on adipogenic regulation and to analyze its relationship with obesity and insulin resistance. DESIGN This was a cross-sectional study in which visceral (VAT) and subcutaneous (SAT) adipose tissue were extracted from 19 morbidly obese, 10 obese, and 10 lean subjects. PTHrP mRNA levels were measured in VAT and SAT. VAT mesenchymal stem cells and 3T3-L1 cells were differentiated into adipocytes in presence or absence of PTHrP siRNA. PTHrP mRNA and protein levels as well as adipogenic markers were evaluated by Western blotting or qPCR. Immunohistochemistry and immunofluorescence procedures were used for PTHrP intracellular localization. RESULTS Both human VAT and SAT express PTHrP protein mainly in the nucleolar compartment of stromal vascular fraction cells. The highest levels of PTHrP mRNA and protein expression were detected in undifferentiated mesenchymal cells and progressively decreased during adipogenesis. Remarkably, adipogenic differentiation in human mesenchymal stem cells (A-hMSC) was significantly impaired in a pthrp knockdown. PTHrP seems to be related to obesity-associated insulin resistance (IR), given that we found that PTHrP mRNA expression was higher in VAT from morbidly obese with a low IR degree (MO-L-IR) subjects than those from morbidly obese with a high IR degree (MO-H-IR) and lean subjects, and correlated positively with body mass index and hip circumference. We also found that A-hMSC from MO-L-IRs displayed higher adipogenic capacity than those from both MO-H-IRs and leans. In addition, adipogenesis was impaired in VAT from MO-H-IRs, given that mRNA expression levels of key adipogenic regulators were lower than those from MO-L-IR subjects. CONCLUSIONS PTHrP could be a potential new therapeutic target for the reprograming of adipogenesis and adipose tissue expansion, thus possibly ameliorating the metabolic syndrome in obese subjects.
Collapse
Affiliation(s)
- María Mar Roca-Rodríguez
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Rajaa El Bekay
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Lourdes Garrido-Sanchez
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - María Gómez-Serrano
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Leticia Coin-Aragüez
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Wilfredo Oliva-Olivera
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Said Lhamyani
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Mercedes Clemente-Postigo
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Eva García-Santos
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Resi de Luna Diaz
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Elena M Yubero-Serrano
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - José M Fernández Real
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Belén Peral
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| | - Francisco J Tinahones
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.M.R.R., R.E., L.G.S., L.C.A., W.O.O., S.L., M.C.P., F.J.T.), Instituto de Investigación Biomédica de Málaga, Complejo Hospitalario de Málaga (Virgen de la Victoria), Universidad de Málaga, CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Málaga, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (M.G.S., E.G.S., B.P.), Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Madrid, Spain; Servicio de Cirugía General y Digestiva (R.d.L.D.), Hospital Universitario Virgen de la Victoria, Málaga, Spain; Lipids and Atherosclerosis Unit (E.M.Y.S.), IMIBIC/Reina Sofia University Hospital/University of Córdoba and CIBEROBN, Instituto de Salud Carlos III, Córdoba, Spain; and Departamento de Diabetes, Endocrinología y Nutrición (J.M.F.R.), Institut d'Investigació Biomèdica de Girona, CIBEROBN e ISCIII, Girona, Spain
| |
Collapse
|
25
|
Clemente-Postigo M, Muñoz-Garach A, Serrano M, Garrido-Sánchez L, Bernal-López MR, Fernández-García D, Moreno-Santos I, Garriga N, Castellano-Castillo D, Camargo A, Fernández-Real JM, Cardona F, Tinahones FJ, Macías-González M. Serum 25-hydroxyvitamin D and adipose tissue vitamin D receptor gene expression: relationship with obesity and type 2 diabetes. J Clin Endocrinol Metab 2015; 100:E591-5. [PMID: 25706239 DOI: 10.1210/jc.2014-3016] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT The relationship between 25-hydroxyvitamin D [25(OH)D] and obesity and type 2 diabetes is not completely understood. Vitamin D receptor (VDR) expression in adipose tissue (AT) is related to obesity and might be regulated by 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. OBJECTIVE To analyze serum 25(OH)D and VDR gene expression in AT according to body mass index (BMI) and glycemic status and the effect of 1,25(OH)2D3 on AT according to BMI. DESIGN AND PATIENTS Two cohorts were studied: 1) 118 subjects classified according to their BMI (lean, overweight, obese, or morbidly obese [MO]) and their glycemic status (normoglycemic [NG] and prediabetic and diabetic [P&D]); and 2) 30 obese subjects (BMI > 30 kg/m(2)) classified as NG and P&D. VDR gene expression was analyzed during preadipocyte differentiation and in vitro stimulation with 1,25(OH)2D3 of AT explants from donors with different BMI values. SETTING University Hospital. MAIN OUTCOME MEASURES Serum 25(OH)D, parathyroid hormone (PTH), and AT VDR gene expression. RESULTS 25(OH)D levels were lower in P&D than NG subjects, significantly so in the lean and MO groups (P < .05). 25(OH)D levels correlated negatively with homeostasis model of assessment for insulin resistance (HOMA-IR) (r = -0.200; P = .032) and glucose (r = -0.295; P = .001), but not with BMI. VDR gene expression was higher in MO than in the other BMI groups (P < .05). 1,25(OH)2D3 increased VDR gene expression in AT from obese patients (P < .05) but not from lean subjects. CONCLUSIONS 25(OH)D levels are diminished in P&D compared to NG subjects, independently of BMI, and are closely related to glucose metabolism variables, suggesting that vitamin D deficiency is associated more with carbohydrate metabolism than with obesity. Moreover, AT has a different response to 1,25(OH)2D3 depending on the degree of obesity.
Collapse
Affiliation(s)
- Mercedes Clemente-Postigo
- Unidad de Gestión Clínica Endocrinología y Nutrición (M.C.-P., A.M.-G., L.G.-S., D.F.-G., D.C.-C., F.C., F.J.T., M.M.-G.), Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Málaga, 29010 Málaga, Spain; Centro de Investigación Biomédica En Red, Pathophysiology of Obesity and Nutrition (CB06/03) (M.C.-P., L.G.-S., D.F.-G., A.C., J.M.F.-R., F.C., F.J.T., M.M.-G.), 28029, Madrid, Spain; Service of Diabetes, Endocrinology, and Nutrition (M.S., N.G., J.M.F.-R.), Institut d'Investigació Biomédica de Girona, 17007 Girona, Spain; Biomedical Research Laboratory (M.R.B.-L.), Internal Medicine Department, IBIMA, Regional University Hospital of Malaga (Carlos Haya Hospital), Universidad de Málaga, 29010 Málaga, Spain; Área del Corazón del Complejo Hospitalario de Málaga (Virgen de la Victoria) (I.M.-S.), IBIMA/Universidad de Malaga, Red de Investigación Cardiovascular, 29010 Málaga, Spain; and Lipid and Atherosclerosis Research Unit (IMIBIC) (A.C.), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Clemente-Postigo M, Roca-Rodriguez MDM, Camargo A, Ocaña-Wilhelmi L, Cardona F, Tinahones FJ. Lipopolysaccharide and lipopolysaccharide-binding protein levels and their relationship to early metabolic improvement after bariatric surgery. Surg Obes Relat Dis 2014; 11:933-9. [PMID: 25737102 DOI: 10.1016/j.soard.2014.11.030] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Revised: 10/31/2014] [Accepted: 11/26/2014] [Indexed: 12/27/2022]
Abstract
BACKGROUND Bariatric surgery usually results in metabolic improvements within a few days from intervention, but the underlying mechanism is not completely understood and may vary depending on the bariatric procedure. Lipopolysaccharides (LPS) from gut microbiota have been proposed as a triggering factor for the inflammatory state in obesity. Roux-en-Y Gastric Bypass (RYGB) leads to a LPS decrease in the medium-term. OBJECTIVE To analyze LPS and LPS-binding protein (LBP) in normoglycemic (NG) and diabetic morbidly obese patients in the short-term after 2 different bariatric surgery procedures. SETTING University Hospital, Spain. METHODS Fifty morbidly obese patients underwent bariatric surgery: 24 with sleeve gastrectomy (SG) and 26 with biliopancreatic diversion (BPD). Patients were classified according to their glycemic status as NG or prediabetic/diabetic. LPS and LBP levels and biochemical and anthropometric variables were determined before and at days 15 and 90 after surgery. RESULTS A significant LPS reduction was seen only in the prediabetic/diabetic patients at 90 days after SG. LBP levels rose at 15 days after BPD but at 90 days returned to baseline in both NG and prediabetic/diabetic patients. At 90 days after SG, LBP levels significantly decreased compared to baseline in NG and prediabetic/diabetic patients. After multivariate analysis only the change in BMI was independently associated with the change in LBP levels at 90 days. None of the changes in biochemical or anthropometrical variables were significantly associated with the changes in LPS levels at 15 days or 90 days. CONCLUSION This is the first study showing that the short-term LPS decrease after bariatric surgery depends on the surgical procedure used as well as on the previous glycemic status of the patient, with SG having the greatest short-term effect on LPS and LBP levels. LBP is closely related to anthropometric variables and may be an inflammatory marker in bariatric surgery patients.
Collapse
Affiliation(s)
- Mercedes Clemente-Postigo
- Unidad de Gestión Clínica Endocrinología y Nutrición. Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Málaga (Spain); CIBER Pathophysiology of obesity and nutrition (CB06/03), Spain.
| | - Maria del Mar Roca-Rodriguez
- Unidad de Gestión Clínica Endocrinología y Nutrición. Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Málaga (Spain); CIBER Pathophysiology of obesity and nutrition (CB06/03), Spain
| | - Antonio Camargo
- Lipid and Atherosclerosis Research Unit (IMIBIC). Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain
| | - Luis Ocaña-Wilhelmi
- Unidad de Gestión Clínica de Cirugía General, Digestiva y Trasplantes. Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria), Málaga, Spain
| | - Fernando Cardona
- Unidad de Gestión Clínica Endocrinología y Nutrición. Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Málaga (Spain); CIBER Pathophysiology of obesity and nutrition (CB06/03), Spain
| | - Francisco J Tinahones
- Unidad de Gestión Clínica Endocrinología y Nutrición. Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Málaga (Spain); CIBER Pathophysiology of obesity and nutrition (CB06/03), Spain.
| |
Collapse
|
27
|
Clemente-Postigo M, Queipo-Ortuño MI, Boto-Ordoñez M, Coin-Aragüez L, Roca-Rodriguez MDM, Delgado-Lista J, Cardona F, Andres-Lacueva C, Tinahones FJ. Effect of acute and chronic red wine consumption on lipopolysaccharide concentrations. Am J Clin Nutr 2013; 97:1053-61. [PMID: 23576043 DOI: 10.3945/ajcn.112.051128] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Chronic red wine (RW) consumption has been associated with decreased cardiovascular disease risk, mainly attributed to an improvement in lipid profile. RW intake is also able to change the composition of gut microbiota. High fat intake has recently been reported to increase metabolic endotoxemia. The gut microbiota has been proposed as the main resource of plasma lipopolysaccharides (LPSs) in metabolic endotoxemia. OBJECTIVE We analyzed the effect on LPS concentrations of chronic RW consumption and acute RW intake in relation to high fat intake in middle-aged men. DESIGN For the chronic study, 10 middle-aged male volunteers were randomly assigned in a crossover trial, and after a washout period, all subjects received RW, dealcoholized red wine (DRW), or gin for 20 d. Serum endotoxin and LPS-binding protein (LBP) concentrations were determined after the washout period and after each of the treatments, and changes in fecal microbiota were quantified. For the acute study, 5 adult men underwent a fat overload or a fat overload together with the consumption of RW, DRW, or gin. Baseline and postprandial serum LPS and LBP concentrations and postprandial chylomicron LPS concentrations were measured. RESULTS There were no significant differences in the change in LPS or LBP concentrations between chronic RW, DRW, and gin consumption. Bifidobacterium and Prevotella amounts were significantly increased by RW and correlated negatively with LPS concentrations. There were no differences in postprandial serum LPS, LBP, or chylomicron LPS concentrations between acute RW, DRW, or gin intake together with a fatty meal. CONCLUSION Chronic RW consumption increases Bifidobacterium and Prevotella amounts, which may have beneficial effects by leading to lower LPS concentrations. This trial was registered at controlled-trials.com as ISRCTN88720134.
Collapse
Affiliation(s)
- Mercedes Clemente-Postigo
- Laboratorio de Investigación Biomédica, Fundación Instituto Mediterráneo para el Avance de la Biotecnología y la Investigación Sanitaria, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Queipo-Ortuño MI, Escoté X, Ceperuelo-Mallafré V, Garrido-Sanchez L, Miranda M, Clemente-Postigo M, Pérez-Pérez R, Peral B, Cardona F, Fernández-Real JM, Tinahones FJ, Vendrell J. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels. PLoS One 2012; 7:e48605. [PMID: 23139800 PMCID: PMC3489666 DOI: 10.1371/journal.pone.0048605] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2012] [Accepted: 09/27/2012] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND FABP4 is predominantly expressed in adipose tissue, and its circulating levels are linked with obesity and a poor atherogenic profile. OBJECTIVE In patients with a wide BMI range, we analyze FABP4 expression in adipose and hepatic tissues in the settings of obesity and insulin resistance. Associations between FABP4 expression in adipose tissue and the FABP4 plasma level as well as the main adipogenic and lipolytic genes expressed in adipose tissue were also analyzed. METHODS The expression of several lipogenic, lipolytic, PPAR family and FABP family genes was analyzed by real time PCR. FABP4 protein expression in total adipose tissues and its fractions were determined by western blot. RESULTS In obesity FABP4 expression was down-regulated (at both mRNA and protein levels), with its levels mainly predicted by ATGL and inversely by the HOMA-IR index. The BMI appeared as the only determinant of the FABP4 variation in both adipose tissue depots. FABP4 plasma levels showed a significant progressive increase according to BMI but no association was detected between FABP4 circulating levels and SAT or VAT FABP4 gene expression. The gene expression of FABP1, FABP4 and FABP5 in hepatic tissue was significantly higher in tissue from the obese IR patients compared to the non-IR group. CONCLUSION The inverse pattern in FABP4 expression between adipose and hepatic tissue observed in morbid obese patients, regarding the IR context, suggests that both tissues may act in a balanced manner. These differences may help us to understand the discrepancies between circulating plasma levels and adipose tissue expression in obesity.
Collapse
Affiliation(s)
- María Isabel Queipo-Ortuño
- Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria (Fundación IMABIS), Málaga, Spain
- CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Xavier Escoté
- Endocrinology and Diabetes Unit.Joan XXIII University Hospital, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Victoria Ceperuelo-Mallafré
- Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria (Fundación IMABIS), Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Lourdes Garrido-Sanchez
- Endocrinology and Diabetes Unit.Joan XXIII University Hospital, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Merce Miranda
- Endocrinology and Diabetes Unit.Joan XXIII University Hospital, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Mercedes Clemente-Postigo
- Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria (Fundación IMABIS), Málaga, Spain
| | - Rafael Pérez-Pérez
- CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
- Instituto de Investigaciones Biomédicas, Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC) & Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Belen Peral
- CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
- Instituto de Investigaciones Biomédicas, Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC) & Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Fernando Cardona
- Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria (Fundación IMABIS), Málaga, Spain
- CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - Jose Manuel Fernández-Real
- CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
- Diabetes, Endocrinology and Nutrition Service, Institut d’Investigació Biomèdica de Girona (IdIBGi), Girona, Spain
| | - Francisco J. Tinahones
- CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
- Servicio Endocrinología y Nutrición del Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - Joan Vendrell
- Endocrinology and Diabetes Unit.Joan XXIII University Hospital, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
29
|
Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R, Cardona Diaz F, Andrés-Lacueva C, Tinahones FJ. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr 2012; 95:1323-34. [PMID: 22552027 DOI: 10.3945/ajcn.111.027847] [Citation(s) in RCA: 429] [Impact Index Per Article: 35.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Few studies have investigated the effect of dietary polyphenols on the complex human gut microbiota, and they focused mainly on single polyphenol molecules and select bacterial populations. OBJECTIVE The objective was to evaluate the effect of a moderate intake of red wine polyphenols on select gut microbial groups implicated in host health benefits. DESIGN Ten healthy male volunteers underwent a randomized, crossover, controlled intervention study. After a washout period, all of the subjects received red wine, the equivalent amount of de-alcoholized red wine, or gin for 20 d each. Total fecal DNA was submitted to polymerase chain reaction(PCR)-denaturing gradient gel electrophoresis and real-time quantitative PCR to monitor and quantify changes in fecal microbiota. Several biochemical markers were measured. RESULTS The dominant bacterial composition did not remain constant over the different intake periods. Compared with baseline, the daily consumption of red wine polyphenol for 4 wk significantly increased the number of Enterococcus, Prevotella, Bacteroides, Bifidobacterium, Bacteroides uniformis, Eggerthella lenta, and Blautia coccoides-Eubacterium rectale groups (P < 0.05). In parallel, systolic and diastolic blood pressures and triglyceride, total cholesterol, HDL cholesterol, and C-reactive protein concentrations decreased significantly (P < 0.05). Moreover, changes in cholesterol and C-reactive protein concentrations were linked to changes in the bifidobacteria number. CONCLUSION This study showed that red wine consumption can significantly modulate the growth of select gut microbiota in humans, which suggests possible prebiotic benefits associated with the inclusion of red wine polyphenols in the diet. This trial was registered at controlled-trials.com as ISRCTN88720134.
Collapse
|
30
|
Clemente-Postigo M, Queipo-Ortuño MI, Murri M, Boto-Ordoñez M, Perez-Martinez P, Andres-Lacueva C, Cardona F, Tinahones FJ. Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. J Lipid Res 2012; 53:973-978. [PMID: 22394503 DOI: 10.1194/jlr.p020909] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The low-grade inflammation observed in obesity has been associated with a high-fat diet, though this relation is not fully understood. Bacterial endotoxin, produced by gut microbiota, may be the linking factor. However, this has not been confirmed in obese patients. To study the relationship between a high-fat diet and bacterial endotoxin, we analyzed postprandial endotoxemia in morbidly obese patients after a fat overload. The endotoxin levels were determined in serum and the chylomicron fraction at baseline and 3 h after a fat overload in 40 morbidly obese patients and their levels related with the degree of insulin resistance and postprandial hypertriglyceridemia. The morbidly obese patients with the highest postprandial hypertriglyceridemia showed a significant increase in lipopolysaccharide (LPS) levels in serum and the chylomicron fraction after the fat overload. Postprandial chylomicron LPS levels correlated positively with the difference between postprandial triglycerides and baseline triglycerides. There were no significant correlations between C-reactive protein (CRP) and LPS levels. The main variables contributing to serum LPS levels after fat overload were baseline and postprandial triglyceride levels but not glucose or insulin resistance. Additionally, superoxide dismutase activity decreased significantly after the fat overload. Postprandial LPS increase after a fat overload is related to postprandial hypertriglyceridemia but not to degree of insulin resistance in morbidly obese patients.
Collapse
Affiliation(s)
- M Clemente-Postigo
- Laboratorio de Investigación Biomédica, Hospital Universitario Virgen de la Victoria, Spain
| | - M I Queipo-Ortuño
- Laboratorio de Investigación Biomédica, Hospital Universitario Virgen de la Victoria, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (06/03), Instituto de Salud Carlos III, Málaga, Spain
| | - M Murri
- Laboratorio de Investigación Biomédica, Hospital Universitario Virgen de la Victoria, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (06/03), Instituto de Salud Carlos III, Málaga, Spain
| | - M Boto-Ordoñez
- Department of Nutrition and Food Science, XaRTA, INSA, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
| | - P Perez-Martinez
- CIBER Fisiopatología de la Obesidad y Nutrición (06/03), Instituto de Salud Carlos III, Málaga, Spain; Lipid and Atherosclerosis Unit, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain
| | - C Andres-Lacueva
- Department of Nutrition and Food Science, XaRTA, INSA, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
| | - F Cardona
- Laboratorio de Investigación Biomédica, Hospital Universitario Virgen de la Victoria, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (06/03), Instituto de Salud Carlos III, Málaga, Spain.
| | - F J Tinahones
- CIBER Fisiopatología de la Obesidad y Nutrición (06/03), Instituto de Salud Carlos III, Málaga, Spain; Fundación IMABIS, and Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Spain
| |
Collapse
|
31
|
Clemente-Postigo M, Queipo-Ortuño MI, Fernandez-Garcia D, Gomez-Huelgas R, Tinahones FJ, Cardona F. Adipose tissue gene expression of factors related to lipid processing in obesity. PLoS One 2011; 6:e24783. [PMID: 21966368 PMCID: PMC3178563 DOI: 10.1371/journal.pone.0024783] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Accepted: 08/17/2011] [Indexed: 12/03/2022] Open
Abstract
Background Adipose tissue lipid storage and processing capacity can be a key factor for obesity-related metabolic disorders such as insulin resistance and diabetes. Lipid uptake is the first step to adipose tissue lipid storage. The aim of this study was to analyze the gene expression of factors involved in lipid uptake and processing in subcutaneous (SAT) and visceral (VAT) adipose tissue according to body mass index (BMI) and the degree of insulin resistance (IR). Methods and Principal Findings VLDL receptor (VLDLR), lipoprotein lipase (LPL), acylation stimulating protein (ASP), LDL receptor-related protein 1 (LRP1) and fatty acid binding protein 4 (FABP4) gene expression was measured in VAT and SAT from 28 morbidly obese patients with Type 2 Diabetes Mellitus (T2DM) or high IR, 10 morbidly obese patients with low IR, 10 obese patients with low IR and 12 lean healthy controls. LPL, FABP4, LRP1 and ASP expression in VAT was higher in lean controls. In SAT, LPL and FABP4 expression were also higher in lean controls. BMI, plasma insulin levels and HOMA-IR correlated negatively with LPL expression in both VAT and SAT as well as with FABP4 expression in VAT. FABP4 gene expression in SAT correlated inversely with BMI and HOMA-IR. However, multiple regression analysis showed that BMI was the main variable contributing to LPL and FABP4 gene expression in both VAT and SAT. Conclusions Morbidly obese patients have a lower gene expression of factors related with lipid uptake and processing in comparison with healthy lean persons.
Collapse
Affiliation(s)
- Mercedes Clemente-Postigo
- Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria, Málaga (Fundación IMABIS), Spain
| | - Maria Isabel Queipo-Ortuño
- Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria, Málaga (Fundación IMABIS), Spain
- CIBER Fisiopatología de la Obesidad y la Nutrición, Spain
| | - Diego Fernandez-Garcia
- CIBER Fisiopatología de la Obesidad y la Nutrición, Spain
- Servicio Endocrinología y Nutrición del Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - Ricardo Gomez-Huelgas
- CIBER Fisiopatología de la Obesidad y la Nutrición, Spain
- Servicio de Medicina Interna del Hospital Regional Carlos Haya, Spain
| | - Francisco J. Tinahones
- CIBER Fisiopatología de la Obesidad y la Nutrición, Spain
- Servicio Endocrinología y Nutrición del Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - Fernando Cardona
- Laboratorio de Investigaciones Biomédicas del Hospital Virgen de la Victoria, Málaga (Fundación IMABIS), Spain
- CIBER Fisiopatología de la Obesidad y la Nutrición, Spain
- * E-mail:
| |
Collapse
|
32
|
Tinahones FJ, Queipo-Ortuño MI, Clemente-Postigo M, Fernnadez-Garcia D, Mingrone G, Cardona F. Postprandial hypertriglyceridemia predicts improvement in insulin resistance in obese patients after bariatric surgery. Surg Obes Relat Dis 2011; 9:213-8. [PMID: 22153002 DOI: 10.1016/j.soard.2011.08.022] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2011] [Revised: 08/04/2011] [Accepted: 08/23/2011] [Indexed: 11/16/2022]
Abstract
BACKGROUND Morbidly obese patients have associated diseases, such as diabetes, hypertension, hyperlipidemia, and cardiovascular disease. Bariatric surgery improves these obesity-related co-morbidities, including insulin resistance. Evidence has shown that patients with morbid obesity have postprandial hypertriglyceridemia (HTG) and that this type of HTG is related to the degree of insulin resistance. Also, bariatric surgery produces a dramatic reduction in triglyceride levels. However, it is unknown whether patients with postprandial HTG have a different clinical evolution after bariatric surgery. The setting of our study was a university hospital. METHODS We studied 57 morbidly obese patients who had mild or severe postprandial HTG after fat overload (<30 mg/dL or >90 mg/dL increase in triglycerides, respectively). All the patients underwent bariatric surgery. After surgery, the anthropometric and biochemical variables and the Homeostasis Model Assessment of Insulin Resistance were measured for 1 year at 0, 15, 30, 45, 90, 180, and 365 days after surgery. RESULTS The patients with more severe postprandial HTG had a greater percentage of change in the Homeostasis Model Assessment of Insulin Resistance at 30, 90, and 180 days after surgery than the patients with less severe postprandial HTG. Multiple regression analysis showed that the postprandial triglyceride levels predict the variation in the Homeostasis Model Assessment of Insulin Resistance index, more so than did traditional variables, such as anthropometric, inflammatory, or hormonal data. CONCLUSION The postprandial HTG level might be the best predictor of improved insulin resistance in morbidly obese patients after bariatric surgery.
Collapse
|
33
|
Clemente-Postigo M, Tinahones F, Cardona F. 162 ADIPOSE TISSUE GENE EXPRESSION OF FACTORS RELATED TO LIPID PROCESSING IN OBESITY. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70163-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Clemente-Postigo M, Queipo-Ortuño M, Valdivielso P, Tinahones F, Cardona F. Effect of apolipoprotein C3 and apolipoprotein A1 polymorphisms on postprandial response to a fat overload in metabolic syndrome patients. Clin Biochem 2010; 43:1300-4. [DOI: 10.1016/j.clinbiochem.2010.08.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2010] [Revised: 07/14/2010] [Accepted: 08/08/2010] [Indexed: 10/19/2022]
|
35
|
Clemente-Postigo M, Queipo-Ortuño M, Tinahones F, Cardona F. P341 EFFECT OF APOCIII SSTI POLYMORPHISM IN POSTPRANDIAL RESPONSE TO A FAT OVERLOAD IN METABOLIC SYNDROME PATIENTS. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70408-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|